Compare CMCM & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMCM | TNYA |
|---|---|---|
| Founded | 2009 | 2016 |
| Country | China | United States |
| Employees | N/A | 70 |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.8M | 171.4M |
| IPO Year | 2014 | 2021 |
| Metric | CMCM | TNYA |
|---|---|---|
| Price | $4.81 | $0.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.33 |
| AVG Volume (30 Days) | 14.8K | ★ 4.7M |
| Earning Date | 06-18-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.96 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.61 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.92 | $0.43 |
| 52 Week High | $9.44 | $2.35 |
| Indicator | CMCM | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 31.99 | 47.05 |
| Support Level | N/A | $0.65 |
| Resistance Level | $7.15 | $0.82 |
| Average True Range (ATR) | 0.27 | 0.09 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 38.28 | 7.60 |
Cheetah Mobile Inc along with its subsidiaries provides comprehensive products and services on PCs and mobile devices. It generates revenue from utility-related business, including advertising services and premium membership services. It also provides multi-cloud management platform and overseas advertising agency service. The company operates in two segments: Internet business, and AI and others. The firm's majority of the revenue is derived from the internet business segment that provides mobile advertising services to advertising customers, as well as selling advertisements and referring user traffic on its mobile and PC platforms. Geographically, it derives the majority of its revenue from the PRC and the rest from Hong Kong, Japan, and the rest of the world.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.